Cambridge Investment Research Advisors
IHE icon

Cambridge Investment Research Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$565K Buy
6,519
+3,654
+128% +$320K ﹤0.01% 2676
2025
Q4 		$243K Buy
+2,865
New +$229K ﹤0.01% 3400
2023
Q2 		– Sell
-3,789
Closed -$221K – 3235
2023
Q1 		$221K Buy
3,789
+288
+8% +$17.3K ﹤0.01% 2747
2022
Q4 		$217K Sell
3,501
-1,146
-25% -$68.9K ﹤0.01% 2687
2022
Q3 		$263K Buy
4,647
+447
+11% +$27.5K ﹤0.01% 2472
2022
Q2 		$268K Sell
4,200
-33
-0.8% -$2.1K ﹤0.01% 2483
2022
Q1 		$274K Sell
4,233
-702
-14% -$44.5K ﹤0.01% 2617
2021
Q4 		$328K Buy
4,935
+123
+3% +$7.8K ﹤0.01% 2444
2021
Q3 		$294K Buy
4,812
+666
+16% +$42.3K ﹤0.01% 2483
2021
Q2 		$257K Buy
+4,146
New +$252K ﹤0.01% 2591
2021
Q1 		– Sell
-5,274
Closed -$315K – 2929
2020
Q4 		$315K Sell
5,274
-66
-1% -$3.76K ﹤0.01% 2093
2020
Q3 		$291K Sell
5,340
-315
-6% -$17K ﹤0.01% 1955
2020
Q2 		$290K Buy
5,655
+594
+12% +$29.9K ﹤0.01% 1909
2020
Q1 		$227K Buy
5,061
+384
+8% +$19.4K ﹤0.01% 1849
2019
Q4 		$250K Buy
4,677
+129
+3% +$6.36K ﹤0.01% 2036
2019
Q3 		$212K Buy
4,548
+135
+3% +$6.46K ﹤0.01% 2071
2019
Q2 		$222K Sell
4,413
-249
-5% -$12.3K ﹤0.01% 1938
2019
Q1 		$239K Sell
4,662
-1,251
-21% -$62.3K ﹤0.01% 1953
2018
Q4 		$277K Sell
5,913
-156
-3% -$8K ﹤0.01% 1710
2018
Q3 		$340K Buy
6,069
+690
+13% +$37.7K ﹤0.01% 1717
2018
Q2 		$271K Buy
5,379
+75
+1% +$3.72K ﹤0.01% 1810
2018
Q1 		$261K Sell
5,304
-462
-8% -$23.7K ﹤0.01% 1772
2017
Q4 		$297K Buy
5,766
+1,884
+49% +$96.8K ﹤0.01% 1667
2017
Q3 		$202K Sell
3,882
-240
-6% -$12.3K ﹤0.01% 1824
2017
Q2 		$213K Sell
4,122
-582
-12% -$29.4K ﹤0.01% 1716
2017
Q1 		$237K Sell
4,704
-1,875
-28% -$92.8K ﹤0.01% 1526
2016
Q4 		$310K Buy
6,579
+180
+3% +$8.54K 0.01% 1253
2016
Q3 		$319K Sell
6,399
-117
-2% -$5.93K 0.01% 1265
2016
Q2 		$314K Buy
6,516
+987
+18% +$47K 0.01% 1155
2016
Q1 		$252K Sell
5,529
-969
-15% -$45.3K 0.01% 1266
2015
Q4 		$350K Sell
6,498
-1,143
-15% -$60.1K 0.01% 1060
2015
Q3 		$377K Sell
7,641
-2,700
-26% -$155K 0.01% 909
2015
Q2 		$603K Buy
10,341
+2,619
+34% +$153K 0.02% 718
2015
Q1 		$444K Buy
7,722
+1,101
+17% +$60.2K 0.01% 855
2014
Q4 		$334K Sell
6,621
-24
-0.4% -$1.17K 0.01% 966
2014
Q3 		$311K Buy
6,645
+1,536
+30% +$69.3K 0.01% 1074
2014
Q2 		$230K Buy
+5,109
New +$220K 0.01% 1131

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Cambridge Investment Research Advisors's IHE Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its iShares US Pharmaceuticals ETF (IHE) stake by 128% in Q1 2026, buying an estimated $320K and bringing the position to 6,519 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

Cambridge Investment Research Advisors first reported a position in IHE in Q2 2014 and has held it in 37 quarters since. The position peaked at $603K in Q2 2015. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

  • Cambridge Investment Research Advisors held 6,519 shares of iShares US Pharmaceuticals ETF worth $565K as of Q1 2026.
  • Cambridge Investment Research Advisors bought 3,654 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $320K.
  • iShares US Pharmaceuticals ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #2676 holding.
  • Cambridge Investment Research Advisors first reported a position in iShares US Pharmaceuticals ETF in Q2 2014 and has held it in 37 quarters since.
  • Cambridge Investment Research Advisors's iShares US Pharmaceuticals ETF position peaked at $603K in Q2 2015.
  • 194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.